Literature DB >> 27284181

IMMUNOTHERAPY. Outsourcing the immune response to cancer.

Mahesh Yadav1, Lélia Delamarre2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27284181     DOI： 10.1126/science.aag1547

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  3 in total

1.  Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Authors:  Hélène Roussel; Eléonore De Guillebon; Lucie Biard; Marion Mandavit; Laure Gibault; Elisabeth Fabre; Martine Antoine; Paul Hofman; Michèle Beau-Faller; Hélène Blons; Claire Danel; Françoise Le Pimpec Barthes; Alain Gey; Clémence Granier; Marie Wislez; Pierre Laurent-Puig; Stéphane Oudard; Patrick Bruneval; Cécile Badoual; Jacques Cadranel; Eric Tartour
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

2.  The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression.

Authors:  Wen Pan; Shu Zhu; Kun Qu; Katrina Meeth; Jijun Cheng; Kaixin He; Hongdi Ma; Yan Liao; Xizhi Wen; Christine Roden; Zuzana Tobiasova; Zheng Wei; Jun Zhao; Jun Liu; Ji Zheng; Bo Guo; Sajid A Khan; Marcus Bosenberg; Richard A Flavell; Jun Lu
Journal:  Immunity       Date:  2017-08-15       Impact factor: 31.745

Review 3.  Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy.

Authors:  Jiawei Tu; Hui Zhang; Jinsui Yu; Chun Liufu; Zhiyi Chen
Journal:  Onco Targets Ther       Date:  2018-09-12       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.